Literature DB >> 19156390

[Opioid-induced immunosuppression. A clinically relevant problem?].

H L Rittner1, A Brack.   

Abstract

Several in vitro and animal studies have demonstrated the immunosuppressive effects of opioids and an increased risk of infection. The clinical relevance of these findings is unclear. In this review the relevant animal and human studies on the relationship of opioid use and risk of infection are summarized. The areas of retroviral infections (i.e. human immunodeficiency virus, HIV), sepsis and pneumonia, postoperative and chronic pain therapy are covered. In the majority of animal studies an increased risk of infection was demonstrated but in human studies these findings were contradictory. However, these studies were frequently underpowered because they involved small patient collectives and do not reflect the standards of evidence-based medicine. In summary, a causal relationship between opioid therapy and an increased risk of infection could neither be conclusively demonstrated nor fully excluded.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19156390     DOI: 10.1007/s00101-008-1498-4

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  68 in total

1.  Morphine synergizes with lipopolysaccharide in a chronic endotoxemia model.

Authors:  S Roy; R G Charboneau; R A Barke
Journal:  J Neuroimmunol       Date:  1999-03-01       Impact factor: 3.478

2.  Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo-controlled trial.

Authors:  Richard Langford; Frank McKenna; Stuart Ratcliffe; Jozef Vojtassák; Ute Richarz
Journal:  Arthritis Rheum       Date:  2006-06

Review 3.  Modulation of immune function by morphine: implications for susceptibility to infection.

Authors:  Sabita Roy; Jinghua Wang; Jennifer Kelschenbach; Lisa Koodie; Josephine Martin
Journal:  J Neuroimmune Pharmacol       Date:  2006-03       Impact factor: 4.147

4.  Enteral naloxone reduces gastric tube reflux and frequency of pneumonia in critical care patients during opioid analgesia.

Authors:  Winfried Meissner; Barbara Dohrn; Konrad Reinhart
Journal:  Crit Care Med       Date:  2003-03       Impact factor: 7.598

5.  Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy.

Authors:  C Peter N Watson; Dwight Moulin; Judith Watt-Watson; Allan Gordon; John Eisenhoffer
Journal:  Pain       Date:  2003-09       Impact factor: 6.961

6.  Virus replication and disease progression inversely correlate with SIV tat evolution in morphine-dependent and SIV/SHIV-infected Indian rhesus macaques.

Authors:  Richard J Noel; Anil Kumar
Journal:  Virology       Date:  2005-11-28       Impact factor: 3.616

7.  Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain.

Authors:  Lynn R Webster; Peter G Butera; Lauren V Moran; Nancy Wu; Lindsay H Burns; Nadav Friedmann
Journal:  J Pain       Date:  2006-12       Impact factor: 5.820

8.  Morphine induces defects in early response of alveolar macrophages to Streptococcus pneumoniae by modulating TLR9-NF-kappa B signaling.

Authors:  Jinghua Wang; Roderick A Barke; Richard Charboneau; Reto Schwendener; Sabita Roy
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

9.  Effects of perioperative central neuraxial analgesia on outcome after coronary artery bypass surgery: a meta-analysis.

Authors:  Spencer S Liu; Brian M Block; Christopher L Wu
Journal:  Anesthesiology       Date:  2004-07       Impact factor: 7.892

10.  Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial.

Authors:  Timothy D Girard; John P Kress; Barry D Fuchs; Jason W W Thomason; William D Schweickert; Brenda T Pun; Darren B Taichman; Jan G Dunn; Anne S Pohlman; Paul A Kinniry; James C Jackson; Angelo E Canonico; Richard W Light; Ayumi K Shintani; Jennifer L Thompson; Sharon M Gordon; Jesse B Hall; Robert S Dittus; Gordon R Bernard; E Wesley Ely
Journal:  Lancet       Date:  2008-01-12       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.